Within the autoimmune space, payers face difficult challenges in decision making. This category has non-exhaustive and non-exclusive populations, making management by indication burdensome. To further complicate the category, indications can be subdivided even further (e.g., by severity, juvenile vs. adult, etc.), increasing the complexity even more.
